Harnessing tumor acidity: innovative lactic acid-responsive promoter enables precision control of CAR-T cell activity in solid tumors
Our LARP strategy exploits tumor acidity as a precise low/high switch for CAR-T cells. By restricting potent CAR expression to the acidic TME while minimizing activity in normal tissues, LAR CAR-T overcomes key barriers of efficacy and OTOT in solid tumors. This lactic acid-sensing paradigm offers a clinically translatable platform for precise immunotherapy.
Authors
- Cuisong Zhu (ORCID: https://orcid.org/0000-0003-3659-1466)
- Yongquan Xue (ORCID: https://orcid.org/0000-0002-1935-8104)
- Yunyu Mao
- Nairong Zheng
- Jiayi Xu (ORCID: https://orcid.org/0000-0003-3465-7927)
- Qibin Liao
- Xiangqing Ding
- Ai Xia
- Lingyan Zhu
- Yangyang Hu
- Linxia Zhang
- Chen Zhao
- Meiqi Feng
- Xiaoyan Zhang
Institutions
- Shanghai Medical College of Fudan University (CN)
- Renji Hospital (CN)
- Shanghai CASB Biotechnology (China) (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Shanghai Public Health Clinical Center (CN)
- Shenzhen Third People’s Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013672
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China